← Back to Search

Advance Care Planning Discussions for Bone Marrow Transplant Patients

N/A
Recruiting
Led By Lori Wiener, Ph.D.
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up follow-up (week 4-9)
Awards & highlights
No Placebo-Only Group

Summary

This trial will study how AYAs with life-threatening illnesses, and their caregivers, benefit from discussing their care values and priorities with a team member before HSCT.

Who is the study for?
This study is for young adults aged 18 to 39 who are about to receive a bone marrow transplant and have enrolled in an NIH study. They must speak English and be able to give informed consent. A caregiver over the age of 18, identified by the patient, can also join. Healthcare providers involved in their care may participate too.
What is being tested?
The trial explores whether discussions on advance care planning (ACP) benefit young patients undergoing stem cell transplants and their caregivers. It involves completing questionnaires and having three detailed conversations about treatment expectations, personal values, support needs, and documenting care preferences.
What are the potential side effects?
Since this trial focuses on conversations rather than medical treatments or drugs, there are no direct physical side effects. However, these discussions might evoke emotional responses due to the sensitive nature of topics like end-of-life care decisions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~follow-up (week 4-9)
This trial's timeline: 3 weeks for screening, Varies for treatment, and follow-up (week 4-9) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acceptability, Emotional impact of intervention
Acceptability, Timing of intervention
Acceptability, qualitative interview
+1 more
Secondary study objectives
Communication quality
Concordance of rankings
Concordance of ratings

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 1 / Assessments and ConversationExperimental Treatment1 Intervention
Baseline and follow-up assessments and conversations at three timepoints
Group II: 2 / SurveyActive Control1 Intervention
Following each AYA/caregiver dyad s completion of timepoint 3, a one-time survey will be sent to a primary clinical attending and APPs who cared for the AYA during the study period

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,958 Previous Clinical Trials
41,112,378 Total Patients Enrolled
Lori Wiener, Ph.D.Principal InvestigatorNational Cancer Institute (NCI)
6 Previous Clinical Trials
1,046 Total Patients Enrolled

Media Library

1 / Assessments and Conversation Clinical Trial Eligibility Overview. Trial Name: NCT05605574 — N/A
Bone Marrow Transplant Research Study Groups: 2 / Survey, 1 / Assessments and Conversation
Bone Marrow Transplant Clinical Trial 2023: 1 / Assessments and Conversation Highlights & Side Effects. Trial Name: NCT05605574 — N/A
1 / Assessments and Conversation 2023 Treatment Timeline for Medical Study. Trial Name: NCT05605574 — N/A
~33 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top